Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that its NETHERTON NOW awareness campaign has surpassed one million video views and generated more than 14 million impressions worldwide.
A Growing Global Platform
Launched to amplify the voices of patients, families, and clinical experts, NETHERTON NOW has emerged as a powerful platform highlighting the daily challenges of Netherton Syndrome (NS), a rare and severe genetic skin disorder. Through a series of compelling videos and personal stories, the campaign has gained international traction across social media and mainstream outlets, including MSN, Today, and CBS News, as well as academic publications such as ScienceDirect.
Denise Carter, Quoin’s Co-Founder and Chief Operating Officer, emphasized the campaign’s impact, “Surpassing one million views and 14 million impressions is a milestone that reflects how far the NETHERTON NOW campaign has come. What began as an idea to raise awareness has become a global platform that brings the harsh realities of living with Netherton Syndrome into the spotlight. We are honored to share the voices of international advocates, patients, families, and clinical experts. Together, these stories are changing how the world understands this devastating disease, building momentum within both the treatment community and the general public, and further reinforce our determination to deliver the first approved treatment.”
Advancing Toward the First Approved Treatment
Alongside its awareness efforts, Quoin continues to advance QRX003, its lead investigational therapy for Netherton Syndrome, which is currently in late-stage clinical trials. The studies are designed to evaluate QRX003 both as a monotherapy and in combination with existing off-label systemic treatments. Recruitment is active across multiple U.S. and international sites, with full enrollment expected in early to mid-Q1 2026.
Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin Pharmaceuticals, highlighted the significance of the program, “As we progress QRX003 through the last stages of clinical development, we remain laser-focused on the possibility of delivering the first approved treatment for Netherton Syndrome. Early data have shown encouraging signals, and these later studies have been designed to support obtaining the broadest possible label for the product. The voices shared in NETHERTON NOW serve as a powerful reminder of the urgent unmet need in this community and strengthen our commitment to advancing meaningful therapies.”
Building Awareness and Momentum
The NETHERTON NOW campaign remains an ongoing initiative from Quoin, aimed at raising global awareness, driving education, and elevating the voices of those directly impacted by Netherton Syndrome. By combining scientific progress with advocacy, Quoin is working to bring both visibility and potential treatment solutions to a community that has long faced limited options.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The company is committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma, and others. For more information, visit www.quoinpharma.com or follow Quoin on LinkedIn for updates.
For more information about Netherton Syndrome, Quoin’s clinical programs, or to stay updated on the NETHERTON NOW series, visit nethertonnow.com.
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Views, Driving Global Awareness of Rare Disease appeared first on PRISM MarketView.
